Literature DB >> 28653193

Effects of ripasudil hydrochloride hydrate (K-115), a Rho-kinase inhibitor, on ocular blood flow and ciliary artery smooth muscle contraction in rabbits.

Yusuke Ohta1, Sanae Takaseki2, Takeshi Yoshitomi2.   

Abstract

PURPOSE: Ripasudil, a Rho-associated coiled-coil-containing protein kinase (ROCK) inhibitor, is a novel drug for glaucoma in Japan. ROCK inhibition not only reduces intraocular pressure (IOP) but also increases ocular blood flow. We investigated the effects of ripasudil on optic disc blood flow (ODBF) in rabbit eyes and in isolated rabbit ciliary arteries.
METHODS: We measured IOP by tonometry and ODBF by laser speckle flowgraphy (LSFG) in male Dutch rabbits. A single drop (20 μL) of 0.8% ripasudil was delivered to the ocular surface after topical application of phenylephrine hydrochloride to reduce the ODBF. The effects of ripasudil on isolated rabbit ciliary artery smooth muscle contractions were measured in vitro with a myograph.
RESULTS: Ripasudil inhibited the reduction of ODBF induced by phenylephrine at 30 and 120 min after instillation (P < .05). The blood flow change was not significantly correlated with the IOP change. Ripasudil induced a concentration-dependent relaxation in isolated rabbit ciliary arteries precontracted with a high-potassium solution. This relaxation was not mediated through the endothelium-dependent activities of nitric oxide synthase, prostacyclin, or the large-conductance calcium-activated K+ channel as shown by the inability of specific inhibitors of these pathways to block the ripasudil-induced relaxation.
CONCLUSIONS: Taken together, our results showed that ripasudil not only decreased IOP but also increased ODBF in rabbits. However, the changes in IOP were not correlated with the changes in ODBF. Ripasudil also induced a concentration-dependent relaxation of isolated rabbit ciliary arteries through a NO-independent mechanism. Further investigation of the effect of ripasudil on ODBF is needed.

Entities:  

Keywords:  Glaucoma; Laser speckle flowgraphy; Ocular blood flow; Rho-kinase inhibitor; Ripasudil

Mesh:

Substances:

Year:  2017        PMID: 28653193     DOI: 10.1007/s10384-017-0524-y

Source DB:  PubMed          Journal:  Jpn J Ophthalmol        ISSN: 0021-5155            Impact factor:   2.447


  48 in total

Review 1.  Literature review and meta-analysis of topical carbonic anhydrase inhibitors and ocular blood flow.

Authors:  Brent Siesky; Alon Harris; Edward Brizendine; Clarice Marques; Jennifer Loh; Joseph Mackey; Jennifer Overton; Peter Netland
Journal:  Surv Ophthalmol       Date:  2009 Jan-Feb       Impact factor: 6.048

2.  [The endothelium and arterial reactivity].

Authors:  P M Vanhoutte
Journal:  J Mal Vasc       Date:  1986

3.  Effect and mechanism of betaxolol and timolol on vascular relaxation in isolated rabbit ciliary artery.

Authors:  Yaru Dong; Hitoshi Ishikawa; Yazhen Wu; Kimiya Shimizu; Toshiaki Goseki; Takeshi Yoshitomi
Journal:  Jpn J Ophthalmol       Date:  2006-12-18       Impact factor: 2.447

4.  Role of endothelial cell hyperpolarization in EDHF-mediated responses in the guinea-pig carotid artery.

Authors:  J F Quignard; M Félétou; G Edwards; J Duhault; A H Weston; P M Vanhoutte
Journal:  Br J Pharmacol       Date:  2000-03       Impact factor: 8.739

5.  Effect of ACh on electrical and mechanical activity in guinea pig coronary arteries.

Authors:  K D Keef; S M Bowen
Journal:  Am J Physiol       Date:  1989-10

6.  Additive Intraocular Pressure-Lowering Effects of the Rho Kinase Inhibitor Ripasudil (K-115) Combined With Timolol or Latanoprost: A Report of 2 Randomized Clinical Trials.

Authors:  Hidenobu Tanihara; Toshihiro Inoue; Tetsuya Yamamoto; Yasuaki Kuwayama; Haruki Abe; Hideki Suganami; Makoto Araie
Journal:  JAMA Ophthalmol       Date:  2015-07       Impact factor: 7.389

7.  Comparison of flow velocity of ophthalmic artery between primary open angle glaucoma and normal tension glaucoma.

Authors:  Y Yamazaki; F Hayamizu
Journal:  Br J Ophthalmol       Date:  1995-08       Impact factor: 4.638

8.  Vasodilatory mechanism of levobunolol on vascular smooth muscle cells.

Authors:  Yaru Dong; Hitoshi Ishikawa; Yazhen Wu; Takeshi Yoshitomi
Journal:  Exp Eye Res       Date:  2007-01-27       Impact factor: 3.467

9.  Targeting of RhoA/ROCK signaling ameliorates progression of diabetic nephropathy independent of glucose control.

Authors:  Vasantha Kolavennu; Lixia Zeng; Hui Peng; Yin Wang; Farhad R Danesh
Journal:  Diabetes       Date:  2007-12-14       Impact factor: 9.461

10.  The therapeutic effects of Rho-ROCK inhibitors on CNS disorders.

Authors:  Takekazu Kubo; Atsushi Yamaguchi; Nobuyoshi Iwata; Toshihide Yamashita
Journal:  Ther Clin Risk Manag       Date:  2008-06       Impact factor: 2.423

View more
  8 in total

Review 1.  Rho kinase inhibitors-a review on the physiology and clinical use in Ophthalmology.

Authors:  Nuno Moura-Coelho; Joana Tavares Ferreira; Carolina Pereira Bruxelas; Marco Dutra-Medeiros; João Paulo Cunha; Rita Pinto Proença
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2019-03-07       Impact factor: 3.117

Review 2.  Impact of the clinical use of ROCK inhibitor on the pathogenesis and treatment of glaucoma.

Authors:  Megumi Honjo; Hidenobu Tanihara
Journal:  Jpn J Ophthalmol       Date:  2018-02-14       Impact factor: 2.447

Review 3.  Status of Rho kinase inhibitors in glaucoma therapeutics-an overview.

Authors:  Bhawesh Chandra Saha; Rashmi Kumari; Rakhi Kushumesh; Anita Ambasta; Bibhuti Prasanna Sinha
Journal:  Int Ophthalmol       Date:  2021-08-27       Impact factor: 2.031

Review 4.  Rho Kinase Inhibitors as a Novel Treatment for Glaucoma and Ocular Hypertension.

Authors:  Angelo P Tanna; Mark Johnson
Journal:  Ophthalmology       Date:  2018-07-12       Impact factor: 12.079

5.  Safety and efficacy of topically administered netarsudil (Rhopressa™) in normal and glaucomatous dogs with ADAMTS10-open-angle glaucoma (ADAMTS10-OAG).

Authors:  Kelly A Leary; Kuan-Ting Lin; Juan P Steibel; Christine D Harman; András M Komáromy
Journal:  Vet Ophthalmol       Date:  2019-12-24       Impact factor: 1.644

Review 6.  [Rho kinase inhibitors as new local therapy option in primary open angle glaucoma].

Authors:  C Erb; K Konieczka
Journal:  Ophthalmologe       Date:  2021-01-05       Impact factor: 1.059

Review 7.  Neuroprotection in glaucoma.

Authors:  C R Vishwaraj; Srinivasan Kavitha; Rengaraj Venkatesh; Aakriti Garg Shukla; Premanand Chandran; Shweta Tripathi
Journal:  Indian J Ophthalmol       Date:  2022-02       Impact factor: 2.969

Review 8.  Newer advances in medical management of glaucoma.

Authors:  Neethu Mohan; Arup Chakrabarti; Nazneen Nazm; Rajvi Mehta; Deepak P Edward
Journal:  Indian J Ophthalmol       Date:  2022-06       Impact factor: 2.969

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.